GSK, Sanofi, AstraZeneca ready to roll out premium-priced flu vaccines

Tracy Staton

Will a new generation of flu shots pay off big for vaccine makers? We'll soon find out. As Reuters reports, several top drug companies are rolling out that fight four strains of influenza, rather than the usual three. And they're expecting to sell those at a big premium.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS